Näytetään tulokset 1 - 10 / 1545
tulosta / sivu
Mitä julkaisutietoja palvelu sisältää?
Julkaisun nimi
Tekijät
Julkaisukanava
Vuosi
 Julkaisujen tiedon ikoni

Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/j.slasd.2023.05.001
Pölläniemi, Angelika; Virtanen, Anniina; Silvennoinen, Olli; Haikarainen, Teemu;
SLAS discovery2023 Julkaisujen tiedon ikoni

Characterization of microstructure and cell wall components of Arabidopsis thaliana overexpressing cyclin-dependent kinase inhibitor 2

Vertaisarvioitu
DOI
10.1023/A:1015840521376
Salmenkallio-Marttila, Marjatta; Aura, Anna-Maria; De Veylder, L.; Inze, Dirk; Oksman-Caldentey, Kir...
Phytochemistry Reviews2002 Julkaisujen tiedon ikoni

PP2A inhibitor PME-1 drives kinase inhibitor resistance in glioma cells

Vertaisarvioitu
DOI
10.1158/0008-5472.can-16-1134
Kaur, Amanpreet; Denisova, Oxana V.; Qiao, Xi; Jumppanen, Mikael; Peuhu, Emilia; Ahmed, Shafiq U.; R...
Cancer research2016 Julkaisujen tiedon ikoni

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

Vertaisarvioitu
Avoin saatavuus
DOI
10.1007/s00432-017-2378-6
Koskela, Hanna L. M.; El Missiry, Mohamed; Ruusila, Anniina; Koskenvesa, Perttu; Bruemmendorf, Tim H...
Journal of cancer research and clinical oncology2017 Julkaisujen tiedon ikoni

Dasatinib targets c-Src kinase in cardiotoxicity

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/j.toxrep.2023.04.013
Elmadani, Manar; Raatikainen, Sami; Mattila, Orvokki; Alakoski, Tarja; Piuhola, Jarkko; Åström, Pirj...
Toxicology reports2023 Julkaisujen tiedon ikoni

Optimizing Tyrosine Kinase Inhibitor Therapy in Gastrointestinal Stromal Tumors: Exploring the Benefits of Continuous Kinase Suppression

Vertaisarvioitu
DOI
10.1634/theoncologist.2012-0361
Le Cesne, Axel; Blay, Jean-Yves; Reichardt, Peter; Joensuu, Heikki
Oncologist2013 Julkaisujen tiedon ikoni

High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro

Vertaisarvioitu
Avoin saatavuus
DOI
10.3390/biom10101365
Torrente, Laura; Maan, Gunjit; Rezig, Asma Oumkaltoum; Quinn, Jean; Jackson, Angus; Grilli, Andrea; ...
Biomolecules2020 Julkaisujen tiedon ikoni

Utilization of Supervised Machine Learning to Understand Kinase Inhibitor Toxophore Profiles

Vertaisarvioitu
Avoin saatavuus
DOI
10.3390/ijms24065088
Bieberich, Andrew A; Asquith, Christopher RM
International journal of molecular sciences2023 Julkaisujen tiedon ikoni

Practical management of tyrosine kinase inhibitor-associated side effects in GIST

Vertaisarvioitu
DOI
10.1016/j.ctrv.2010.04.008
Joensuu, Heikki; Trent, Jonathan C.; Reichardt, Peter
Cancer treatment reviews2011 Julkaisujen tiedon ikoni

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/j.leukres.2020.106310
Soderlund, Stina; Persson, Inger; Ilanderd, Mette; Guilhot, Joelle; Hjorth-Hansen, Henrik; Koskenves...
Leukemia research2020

Development of an enzyme-coupled activity assay for Janus kinase 2 inhibitor screening

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/j.slasd.2023.05.001
2023

Characterization of microstructure and cell wall components of Arabidopsis thaliana overexpressing cyclin-dependent kinase inhibitor 2

Vertaisarvioitu
DOI
10.1023/A:1015840521376
2002

PP2A inhibitor PME-1 drives kinase inhibitor resistance in glioma cells

Vertaisarvioitu
DOI
10.1158/0008-5472.can-16-1134
2016

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

Vertaisarvioitu
Avoin saatavuus
DOI
10.1007/s00432-017-2378-6
2017

Dasatinib targets c-Src kinase in cardiotoxicity

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/j.toxrep.2023.04.013
2023

Optimizing Tyrosine Kinase Inhibitor Therapy in Gastrointestinal Stromal Tumors: Exploring the Benefits of Continuous Kinase Suppression

Vertaisarvioitu
DOI
10.1634/theoncologist.2012-0361
2013

High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro

Vertaisarvioitu
Avoin saatavuus
DOI
10.3390/biom10101365
2020

Utilization of Supervised Machine Learning to Understand Kinase Inhibitor Toxophore Profiles

Vertaisarvioitu
Avoin saatavuus
DOI
10.3390/ijms24065088
2023

Practical management of tyrosine kinase inhibitor-associated side effects in GIST

Vertaisarvioitu
DOI
10.1016/j.ctrv.2010.04.008
2011

Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy

Vertaisarvioitu
Avoin saatavuus
DOI
10.1016/j.leukres.2020.106310
2020